Note: The comments under each article title are the opinion of our president, Al Musella, DPM, and do not reflect official policy of the Musella Foundation!
09/20/18 Experimental drug 'nothing short of miraculous' for father of 4 with super-rare brain tumor
This is the drug that we recently gave a million dollar grant to help support and speed up it's development! The mutation (H3K27 M) is very common in DIPG, and common in midline and thalmic malignant gliomas, more so in younger GBM patients. This experimental drug is in clinical trials. Check your pathology report to see if you have this mutation. If you do, contact us and we can help you find a trial. (It is so common in DIPG that no biopsy is needed to get into the trials for that tumor type - it is assumed they all have this)
09/10/18 Patient Foundation Collaboration to Advance ONC201 in DIPG and other H3 K27M-mutant Gliomas
This project will speed up the development of a drug (Onc-201) that has shown promise in early trials for DIPG as well as high grade gliomas that have a specific mutation called H3 K27m. If you have DIPG or a high grade glioma with that mutation, give us a call.
This is a one million dollar grant, to be paid in 4 equal payments over the next 3 years. We gave the first $250,000 payment today! I am going to need help raising the rest of the money! This is one of the most important projects that we have ever worked on and we need to raise the money for the next payment in a few months. Contact us for details.
09/01/18 This brain cancer drug stock has been on a tear
I usually do not report on financial stuff, but this is good news for the brain tumor community. It shows that a brain tumor treatment can be a financial success and this will encourage other companies to enter this space!